A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Study ID
NCT05042375
Phase
PHASE3
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • camrelizumab + famitinib — DRUG
    Camrelizumab for injection, 200 mg; Famitinib malate capsules, 20 mg.
  • pembrolizumab — DRUG
    pembrolizumab 200 mg.
  • camrelizumab — DRUG
    Camrelizumab for injection, 200 mg.

Study Details

The study is being conducted to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate vs. pembrolizumab in treatment naïve subjects with programmed death-ligand 1(PD-L1)-positive recurrent or metastatic non-small cell lung cancer (NSCLC).

Key Dates

Start date
Sep 8, 2022
Status verified
Oct 2022
Primary completion
Dec 31, 2023
Completion
Dec 31, 2025

Study Design

Enrollment
450 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: camrelizumab + famitinib
  • Experimental: pembrolizumab
  • Experimental: camrelizumab

Primary Outcome Measure

PFS assessed by BIRC [ Time Frame: up to 3 years ]

Central Contacts

Related Studies